Work

Abstract CT161: A Phase II study of the polo-like kinase (PLK1) inhibitor onvansertib in combination with abiraterone (abi) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Year: 2019

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2019-ct161

Authors: David J. Einstein, Atish Choudhury, Philip Saylor, Lillian Werner, Mark Erlander, Maya Ridinger, Glenn Bubley

Institutions: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Massachusetts General Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2954987754

Cites:

Cited by: 1

Related to: 10